Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

Article Abstract:

The drug miltefosine appears to be effective in treating visceral leishmaniasis. This disease, which is also called kala-azar, is an infection by the parasite Leishmania. There are very few effective treatments for this disease. Researchers assigned 120 patients with visceral leishmaniasis to take various dosages of the drug. The lowest dose was 50 milligrams per day and the highest was 150 milligrams per day. All 120 patients were initially cured but 6 had a relapse. The remaining 114 had not relapsed six months after treatment. Sixty-two percent had a gastrointestinal side effect from the drug.

---

Miltefosine -- the long-awaited therapy for visceral leishmaniasis?

Article Abstract:

The drug miltefosine may be one of the first effective treatments for visceral leishmaniasis that can be taken by mouth. Visceral leishmaniasis, also called kala-azar, is a parasitic disease that strikes about 500,000 people every year. The only treatments are pentavalent antimony compounds and amphotericin B, but both must be given intravenously. Intravenous drugs are also expensive, putting them out of reach of people in developing countries who need them most. A 1999 study found that miltefosine, originally an anti-cancer drug, cured kala-azar in 95% of the people who took it.

Editorial

---

Injectable Paromomycin for Visceral Leishmaniasis in India

Article Abstract:

The fatal disease Kala-azar prevalent in India treated through alternative medicines and the encouraging results are discussed.

India, Health aspects, Dosage and administration, Aminoglycosides, Clinical report

Similar abstracts:

• Abstracts: A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure
• Abstracts: A randomized trial of surgery in the treatment of single metastases to the brain. Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial
• Abstracts: Potential for the transmission of HIV-1 despite highly active antiretroviral therapy. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy
• Abstracts: Dousing the flames. Burns assessment and initial management
• Abstracts: Pilot randomized controlled trial of Chinese herbal treatment for HIV-associated symptoms. Human herpesvirus 8 oral shedding in HIV-infected men with and without Kaposi Sarcoma

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.